-
Something wrong with this record ?
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion
M. Borsky, V. Hrabcakova, J. Novotna, Y. Brychtova, M. Doubek, A. Panovska, P. Muller, J. Mayer, M. Trbusek, M. Mraz
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell blood drug therapy immunology pathology MeSH
- Cytotoxicity, Immunologic immunology MeSH
- Complement System Proteins immunology MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Antineoplastic Agents, Immunological therapeutic use MeSH
- Rituximab therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement-dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in ∼20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4dimCD5bright intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time-to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011839
- 003
- CZ-PrNML
- 005
- 20220506130106.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2021.106684 $2 doi
- 035 __
- $a (PubMed)34438120
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Borsky, Marek $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 245 10
- $a Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion / $c M. Borsky, V. Hrabcakova, J. Novotna, Y. Brychtova, M. Doubek, A. Panovska, P. Muller, J. Mayer, M. Trbusek, M. Mraz
- 520 9_
- $a The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity of complement-dependent cytotoxicity (CDC). The absolute amount of cell-surface CD20 molecules (CD20 density x CLL lymphocytosis) was a predictor for complement exhaustion during therapy. We also describe that a highly variable decrease in CLL cell counts at 5 h (88 %-2%) following rituximab infusion is accompanied in most patients by peripheral blood repopulation with CLL cells at 24 h, and in ∼20 % of patients, this resulted in CLL counts higher than before therapy. We provide evidence that CLL cells recrudescence is linked with i) CDC exhaustion, which leads to the formation of an insufficient amount of membrane attack complexes, likely resulting in temporary retention of surviving rituximab-opsonized cells by the mononuclear-phagocyte system (followed by their release back to blood), and ii) CLL cells regression from immune niches (CXCR4dimCD5bright intraclonal subpopulation). Patients with major peripheral blood CLL cell repopulation exhibited a longer time-to-progression after chemoimmunotherapy compared to patients with lower or no repopulation, suggesting chemotherapy vulnerability of CLL cells that repopulate the blood.
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
- 650 _2
- $a komplement $x imunologie $7 D003165
- 650 _2
- $a cytotoxicita imunologická $x imunologie $7 D003602
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x krev $x farmakoterapie $x imunologie $x patologie $7 D015451
- 650 _2
- $a rituximab $x terapeutické užití $7 D000069283
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hrabcakova, Viera $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Novotna, Jitka $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Brychtova, Yvona $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Doubek, Michael $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Panovska, Anna $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Muller, Petr $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic
- 700 1_
- $a Mayer, Jiri $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic
- 700 1_
- $a Trbusek, Martin $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic. Electronic address: m.trbusek@volny.cz
- 700 1_
- $a Mraz, Marek $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Center of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: marek.mraz@email.cz
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 111, č. - (2021), s. 106684
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34438120 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130058 $b ABA008
- 999 __
- $a ok $b bmc $g 1789445 $s 1163040
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 111 $c - $d 106684 $e 20210804 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- LZP __
- $a Pubmed-20220425